Effects Dapagliflozin on Inflammatory Markers Erythropoiesis and Iron Metabolism in Patients with Type 2 Diabetes and CKD

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

210

Participants

Timeline

Start Date

March 1, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

May 1, 2027

Conditions

Chronic Kidney DiseasesDiabetes Type 2

Interventions

DRUG

Dapagliflozin (DAPA)

patient will recive dapagliflozin for 24 week to improvement of eGFR on CKD patients

DRUG

Placebo

type 2 diabetic patients with chronic kidney diseases will recive placebo for 24 weeks

All Listed Sponsors

lead

Assiut University

OTHER